Ziming Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

Advanced Non Small Cell Lung Cancer

Circulating Tumor

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

NPJ precision oncology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Zhuo Chen, Wenxiang Ji, Wenxin Feng, Jingchuan Cui, Yuchen Wang, Fan Li, Jiachen Chen, Ziheng Guo, Liliang Xia, Xiaokuan Zhu, Xiaomin Niu, Yanshuang Zhang, Ziming Li, Alice Sze Tsai Wong, Shun Lu, Wei-Liang Xia
PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer. Science translational medicine 16 (763) (2024)
Xiaohan Shen, Jiao Dai, Lingchuan Guo, Zhigang Liu, Liu Yang, Dongmei Gu, Yinghong Xie, Zhuo Wang, Ziming Li, Haimiao Xu, Qihui Shi
Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis. NPJ precision oncology 8 (1) (2024)
Xiaohan Shen, Jiao Dai, Lingchuan Guo, Zhigang Liu, Liu Yang, Dongmei Gu, Yinghong Xie, Zhuo Wang, Ziming Li, Haimiao Xu, Qihui Shi
Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis. NPJ precision oncology 8 (1) (2024)
Ziming Li, Shun Lu
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (6) (2023)
Ziming Li, Shun Lu
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (6) (2023)
Ziming Li, Shun Lu
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)